Taligen Therapeutics CEO Abbie Celniker Honored with Mass High Tech 2010 All-Star Award

Recognized as one of the dynamic and influential leaders of New England’s Innovation Economy

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that Abbie Celniker, Ph.D., CEO of Taligen Therapeutics was among the recipients of the Mass High Tech, Voice of New England Innovation, 2010 All-Star Awards. The All-Star Awards recognize 16 dynamic and influential leaders of New England’s innovation economy. This is the 15th year of the awards program.

“I am honored to have received this recognition by Mass High Tech. The local biotechnology industry has long been a key contributor to economic growth in our community. Based on my recent interactions with the Mass Life Sciences Center and the Massachusetts Biotechnology Council, I believe now more than ever, that biotechnology will continue to accelerate innovation and drive employment in New England for the foreseeable future,” said Abbie Celniker, Ph.D., President and CEO of Taligen Therapeutics.

About the 2010 Mass High Tech All-Star Awards:

The 2010 Mass High Tech All-Stars honorees represent a broad range of technology and service sectors, including robotics, mobile technology, hardware, health care, Internet and biotech. They were selected from more than 200 nominees recommended by the technology community.

The honorees were profiled in a special edition of Mass High Tech on October 27 and were recognized at an evening awards celebration and networking reception on Thursday, October 28 at the Intercontinental Hotel in Boston. More information about the event is available at http://masshightech.bizjournals.com/masshightech/event/26971 .

About Taligen Therapeutics

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen’s targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. For additional information about the Company, please visit www.taligentherapeutics.com.



CONTACT:

The Yates Network
Gina Nugent, 617-460-3579

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.